Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction : Results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial
Identifieur interne : 000392 ( PascalFrancis/Curation ); précédent : 000391; suivant : 000393Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction : Results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial
Auteurs : Eric J. Topol [États-Unis] ; E. Magnus Ohman [États-Unis] ; Paul W. Armstrong [Canada] ; Robert Wilcox [Royaume-Uni] ; Alan M. Skene [Royaume-Uni] ; Philip Aylward [Australie] ; John Simes [Australie] ; Anthony Dalby [Afrique du Sud] ; Amadeo Betriu [Espagne] ; Christoph Bode [Allemagne] ; Harvey D. White [Nouvelle-Zélande] ; Judith S. Hochman [États-Unis] ; Hakan Emanuelson [Royaume-Uni] ; Alec Vahanian [France] ; Shelly Sapp [États-Unis] ; Amanda Stebbins [États-Unis] ; David J. Moliterno [États-Unis] ; Robert M. Califf [États-Unis]Source :
- Circulation : (New York, N.Y.) [ 0009-7322 ] ; 2000.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
Background-New recombinant plasminogen activators have been developed to simulate the fibrinolytic action of the physiological serine protease tissue plasminogen activator (alteplase, t-PA), and have prolonged half-life features permitting bolus administration. One such activator, reteplase (r-PA), was compared with t-PA in the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-III Trial. Methods and Results-At 1-year follow-up, survival status was ascertained in 97.4% of the 15 059 patients enrolled in the GUSTO-III trial. At 1 year, the mortality rate for the t-PA-assigned group was 11.06%, and for r-PA it was 11.20% (P=0.77). The absolute mortality difference of 0.14% has 95% CIs of - 1.21% to 0.93%. There were no significant differences in outcome by intention-to-treat for the 2 different plasminogen activators in the prespecified groups (age, infarct location, time-to-treatment). The absolute difference in mortality rates between t-PA and r-PA progressively narrowed over the predetermined observation times after random assignment; it was 0.31% at 24 hours, 0.26% at 7 days, 0.23% at 30 days, and 0.14% at I year. Of note, mortality rate in the trial between 30 days and I year in 13 883 patients was 4.02% and did not differ between the treatment groups. However, this mortality rate was substantially greater than in GUSTO-I, in which mortality rate for t-PA versus streptokinase between 30 days and 1-year was 2.97% (heart rate 1.36, 95% CI 1.23, 1.50, P<0.001). Conclusions-The r-PA and t-PA strategies yielded similar survival outcomes after 30 days in this trial. The increase in mortality rate during extended follow-up compared with previous trials may reflect higher-risk patients and highlights the need for improved secondary prevention strategies.
| pA |
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :005D78
Links to Exploration step
Pascal:00-0521832Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction : Results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial</title><author><name sortKey="Topol, Eric J" sort="Topol, Eric J" uniqKey="Topol E" first="Eric J." last="Topol">Eric J. Topol</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>The Cleveland Clinic Foundation</s1><s2>Cleveland, Ohio</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>15 aut.</sZ><sZ>17 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Ohman, E Magnus" sort="Ohman, E Magnus" uniqKey="Ohman E" first="E. Magnus" last="Ohman">E. Magnus Ohman</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Duke University</s1><s2>Durham, NC</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>16 aut.</sZ><sZ>18 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Armstrong, Paul W" sort="Armstrong, Paul W" uniqKey="Armstrong P" first="Paul W." last="Armstrong">Paul W. Armstrong</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>University of Alberta</s1><s2>Edmonton</s2><s3>CAN</s3><sZ>3 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Wilcox, Robert" sort="Wilcox, Robert" uniqKey="Wilcox R" first="Robert" last="Wilcox">Robert Wilcox</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Queen's Medical Center University Hospital</s1><s2>Nottingham</s2><s3>GBR</s3><sZ>4 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Skene, Alan M" sort="Skene, Alan M" uniqKey="Skene A" first="Alan M." last="Skene">Alan M. Skene</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Nottingham Clinical Trials Data Center</s1><s2>Nottingham</s2><s3>GBR</s3><sZ>5 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Aylward, Philip" sort="Aylward, Philip" uniqKey="Aylward P" first="Philip" last="Aylward">Philip Aylward</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Flinders Medical Center</s1><s2>Bedford Park</s2><s3>AUS</s3><sZ>6 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Simes, John" sort="Simes, John" uniqKey="Simes J" first="John" last="Simes">John Simes</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>University of Sydney</s1><s2>New South Wales</s2><s3>AUS</s3><sZ>7 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Dalby, Anthony" sort="Dalby, Anthony" uniqKey="Dalby A" first="Anthony" last="Dalby">Anthony Dalby</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Milpark Hospital</s1><s2>Johannesburg</s2><s3>ZAF</s3><sZ>8 aut.</sZ></inist:fA14><country>Afrique du Sud</country></affiliation></author><author><name sortKey="Betriu, Amadeo" sort="Betriu, Amadeo" uniqKey="Betriu A" first="Amadeo" last="Betriu">Amadeo Betriu</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Hospital Clinic, University of Barcelona</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>9 aut.</sZ></inist:fA14><country>Espagne</country></affiliation></author><author><name sortKey="Bode, Christoph" sort="Bode, Christoph" uniqKey="Bode C" first="Christoph" last="Bode">Christoph Bode</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Medical Clinic of the University of Heidelberg</s1><s2>Heidelberg</s2><s3>DEU</s3><sZ>10 aut.</sZ></inist:fA14><country>Allemagne</country></affiliation></author><author><name sortKey="White, Harvey D" sort="White, Harvey D" uniqKey="White H" first="Harvey D." last="White">Harvey D. White</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Green Lane Hospital</s1><s2>Auckland</s2><s3>NZL</s3><sZ>11 aut.</sZ></inist:fA14><country>Nouvelle-Zélande</country></affiliation></author><author><name sortKey="Hochman, Judith S" sort="Hochman, Judith S" uniqKey="Hochman J" first="Judith S." last="Hochman">Judith S. Hochman</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>New Zealand; St Lukes-Roosevelt Hospital Center</s1><s2>New York, NY</s2><s3>USA</s3><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Emanuelson, Hakan" sort="Emanuelson, Hakan" uniqKey="Emanuelson H" first="Hakan" last="Emanuelson">Hakan Emanuelson</name><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Astra Charnwood Clinical R & D</s1><s2>Loughborough</s2><s3>GBR</s3><sZ>13 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Vahanian, Alec" sort="Vahanian, Alec" uniqKey="Vahanian A" first="Alec" last="Vahanian">Alec Vahanian</name><affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Hospital Bichat</s1><s2>Paris</s2><s3>FRA</s3><sZ>14 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Sapp, Shelly" sort="Sapp, Shelly" uniqKey="Sapp S" first="Shelly" last="Sapp">Shelly Sapp</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>The Cleveland Clinic Foundation</s1><s2>Cleveland, Ohio</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>15 aut.</sZ><sZ>17 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Stebbins, Amanda" sort="Stebbins, Amanda" uniqKey="Stebbins A" first="Amanda" last="Stebbins">Amanda Stebbins</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Duke University</s1><s2>Durham, NC</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>16 aut.</sZ><sZ>18 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Moliterno, David J" sort="Moliterno, David J" uniqKey="Moliterno D" first="David J." last="Moliterno">David J. Moliterno</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>The Cleveland Clinic Foundation</s1><s2>Cleveland, Ohio</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>15 aut.</sZ><sZ>17 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Califf, Robert M" sort="Califf, Robert M" uniqKey="Califf R" first="Robert M." last="Califf">Robert M. Califf</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Duke University</s1><s2>Durham, NC</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>16 aut.</sZ><sZ>18 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">00-0521832</idno><date when="2000">2000</date><idno type="stanalyst">PASCAL 00-0521832 INIST</idno><idno type="RBID">Pascal:00-0521832</idno><idno type="wicri:Area/PascalFrancis/Corpus">005D78</idno><idno type="wicri:Area/PascalFrancis/Curation">000392</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction : Results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial</title><author><name sortKey="Topol, Eric J" sort="Topol, Eric J" uniqKey="Topol E" first="Eric J." last="Topol">Eric J. Topol</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>The Cleveland Clinic Foundation</s1><s2>Cleveland, Ohio</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>15 aut.</sZ><sZ>17 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Ohman, E Magnus" sort="Ohman, E Magnus" uniqKey="Ohman E" first="E. Magnus" last="Ohman">E. Magnus Ohman</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Duke University</s1><s2>Durham, NC</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>16 aut.</sZ><sZ>18 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Armstrong, Paul W" sort="Armstrong, Paul W" uniqKey="Armstrong P" first="Paul W." last="Armstrong">Paul W. Armstrong</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>University of Alberta</s1><s2>Edmonton</s2><s3>CAN</s3><sZ>3 aut.</sZ></inist:fA14><country>Canada</country></affiliation></author><author><name sortKey="Wilcox, Robert" sort="Wilcox, Robert" uniqKey="Wilcox R" first="Robert" last="Wilcox">Robert Wilcox</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Queen's Medical Center University Hospital</s1><s2>Nottingham</s2><s3>GBR</s3><sZ>4 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Skene, Alan M" sort="Skene, Alan M" uniqKey="Skene A" first="Alan M." last="Skene">Alan M. Skene</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Nottingham Clinical Trials Data Center</s1><s2>Nottingham</s2><s3>GBR</s3><sZ>5 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Aylward, Philip" sort="Aylward, Philip" uniqKey="Aylward P" first="Philip" last="Aylward">Philip Aylward</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Flinders Medical Center</s1><s2>Bedford Park</s2><s3>AUS</s3><sZ>6 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Simes, John" sort="Simes, John" uniqKey="Simes J" first="John" last="Simes">John Simes</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>University of Sydney</s1><s2>New South Wales</s2><s3>AUS</s3><sZ>7 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Dalby, Anthony" sort="Dalby, Anthony" uniqKey="Dalby A" first="Anthony" last="Dalby">Anthony Dalby</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Milpark Hospital</s1><s2>Johannesburg</s2><s3>ZAF</s3><sZ>8 aut.</sZ></inist:fA14><country>Afrique du Sud</country></affiliation></author><author><name sortKey="Betriu, Amadeo" sort="Betriu, Amadeo" uniqKey="Betriu A" first="Amadeo" last="Betriu">Amadeo Betriu</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Hospital Clinic, University of Barcelona</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>9 aut.</sZ></inist:fA14><country>Espagne</country></affiliation></author><author><name sortKey="Bode, Christoph" sort="Bode, Christoph" uniqKey="Bode C" first="Christoph" last="Bode">Christoph Bode</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Medical Clinic of the University of Heidelberg</s1><s2>Heidelberg</s2><s3>DEU</s3><sZ>10 aut.</sZ></inist:fA14><country>Allemagne</country></affiliation></author><author><name sortKey="White, Harvey D" sort="White, Harvey D" uniqKey="White H" first="Harvey D." last="White">Harvey D. White</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Green Lane Hospital</s1><s2>Auckland</s2><s3>NZL</s3><sZ>11 aut.</sZ></inist:fA14><country>Nouvelle-Zélande</country></affiliation></author><author><name sortKey="Hochman, Judith S" sort="Hochman, Judith S" uniqKey="Hochman J" first="Judith S." last="Hochman">Judith S. Hochman</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>New Zealand; St Lukes-Roosevelt Hospital Center</s1><s2>New York, NY</s2><s3>USA</s3><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Emanuelson, Hakan" sort="Emanuelson, Hakan" uniqKey="Emanuelson H" first="Hakan" last="Emanuelson">Hakan Emanuelson</name><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Astra Charnwood Clinical R & D</s1><s2>Loughborough</s2><s3>GBR</s3><sZ>13 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Vahanian, Alec" sort="Vahanian, Alec" uniqKey="Vahanian A" first="Alec" last="Vahanian">Alec Vahanian</name><affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Hospital Bichat</s1><s2>Paris</s2><s3>FRA</s3><sZ>14 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Sapp, Shelly" sort="Sapp, Shelly" uniqKey="Sapp S" first="Shelly" last="Sapp">Shelly Sapp</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>The Cleveland Clinic Foundation</s1><s2>Cleveland, Ohio</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>15 aut.</sZ><sZ>17 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Stebbins, Amanda" sort="Stebbins, Amanda" uniqKey="Stebbins A" first="Amanda" last="Stebbins">Amanda Stebbins</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Duke University</s1><s2>Durham, NC</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>16 aut.</sZ><sZ>18 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Moliterno, David J" sort="Moliterno, David J" uniqKey="Moliterno D" first="David J." last="Moliterno">David J. Moliterno</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>The Cleveland Clinic Foundation</s1><s2>Cleveland, Ohio</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>15 aut.</sZ><sZ>17 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Califf, Robert M" sort="Califf, Robert M" uniqKey="Califf R" first="Robert M." last="Califf">Robert M. Califf</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Duke University</s1><s2>Durham, NC</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>16 aut.</sZ><sZ>18 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author></analytic><series><title level="j" type="main">Circulation : (New York, N.Y.)</title><title level="j" type="abbreviated">Circulation : (N. Y. N.Y.)</title><idno type="ISSN">0009-7322</idno><imprint><date when="2000">2000</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Circulation : (New York, N.Y.)</title><title level="j" type="abbreviated">Circulation : (N. Y. N.Y.)</title><idno type="ISSN">0009-7322</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acute</term><term>Alteplase</term><term>Chemotherapy</term><term>Fibrinolytic</term><term>Follow up study</term><term>Human</term><term>Infarct</term><term>Myocardium</term><term>Prognosis</term><term>Reteplase</term><term>Streptokinase</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Infarctus</term><term>Myocarde</term><term>Aigu</term><term>Altéplase</term><term>Rétéplase</term><term>Streptokinase</term><term>Chimiothérapie</term><term>Traitement</term><term>Pronostic</term><term>Homme</term><term>Etude longitudinale</term><term>Fibrinolytique</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background-New recombinant plasminogen activators have been developed to simulate the fibrinolytic action of the physiological serine protease tissue plasminogen activator (alteplase, t-PA), and have prolonged half-life features permitting bolus administration. One such activator, reteplase (r-PA), was compared with t-PA in the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-III Trial. Methods and Results-At 1-year follow-up, survival status was ascertained in 97.4% of the 15 059 patients enrolled in the GUSTO-III trial. At 1 year, the mortality rate for the t-PA-assigned group was 11.06%, and for r-PA it was 11.20% (P=0.77). The absolute mortality difference of 0.14% has 95% CIs of - 1.21% to 0.93%. There were no significant differences in outcome by intention-to-treat for the 2 different plasminogen activators in the prespecified groups (age, infarct location, time-to-treatment). The absolute difference in mortality rates between t-PA and r-PA progressively narrowed over the predetermined observation times after random assignment; it was 0.31% at 24 hours, 0.26% at 7 days, 0.23% at 30 days, and 0.14% at I year. Of note, mortality rate in the trial between 30 days and I year in 13 883 patients was 4.02% and did not differ between the treatment groups. However, this mortality rate was substantially greater than in GUSTO-I, in which mortality rate for t-PA versus streptokinase between 30 days and 1-year was 2.97% (heart rate 1.36, 95% CI 1.23, 1.50, P<0.001). Conclusions-The r-PA and t-PA strategies yielded similar survival outcomes after 30 days in this trial. The increase in mortality rate during extended follow-up compared with previous trials may reflect higher-risk patients and highlights the need for improved secondary prevention strategies.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0009-7322</s0></fA01><fA02 i1="01"><s0>CIRCAZ</s0></fA02><fA03 i2="1"><s0>Circulation : (N. Y. N.Y.)</s0></fA03><fA05><s2>102</s2></fA05><fA06><s2>15</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction : Results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial</s1></fA08><fA11 i1="01" i2="1"><s1>TOPOL (Eric J.)</s1></fA11><fA11 i1="02" i2="1"><s1>OHMAN (E. Magnus)</s1></fA11><fA11 i1="03" i2="1"><s1>ARMSTRONG (Paul W.)</s1></fA11><fA11 i1="04" i2="1"><s1>WILCOX (Robert)</s1></fA11><fA11 i1="05" i2="1"><s1>SKENE (Alan M.)</s1></fA11><fA11 i1="06" i2="1"><s1>AYLWARD (Philip)</s1></fA11><fA11 i1="07" i2="1"><s1>SIMES (John)</s1></fA11><fA11 i1="08" i2="1"><s1>DALBY (Anthony)</s1></fA11><fA11 i1="09" i2="1"><s1>BETRIU (Amadeo)</s1></fA11><fA11 i1="10" i2="1"><s1>BODE (Christoph)</s1></fA11><fA11 i1="11" i2="1"><s1>WHITE (Harvey D.)</s1></fA11><fA11 i1="12" i2="1"><s1>HOCHMAN (Judith S.)</s1></fA11><fA11 i1="13" i2="1"><s1>EMANUELSON (Hakan)</s1></fA11><fA11 i1="14" i2="1"><s1>VAHANIAN (Alec)</s1></fA11><fA11 i1="15" i2="1"><s1>SAPP (Shelly)</s1></fA11><fA11 i1="16" i2="1"><s1>STEBBINS (Amanda)</s1></fA11><fA11 i1="17" i2="1"><s1>MOLITERNO (David J.)</s1></fA11><fA11 i1="18" i2="1"><s1>CALIFF (Robert M.)</s1></fA11><fA14 i1="01"><s1>The Cleveland Clinic Foundation</s1><s2>Cleveland, Ohio</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>15 aut.</sZ><sZ>17 aut.</sZ></fA14><fA14 i1="02"><s1>Duke University</s1><s2>Durham, NC</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>16 aut.</sZ><sZ>18 aut.</sZ></fA14><fA14 i1="03"><s1>University of Alberta</s1><s2>Edmonton</s2><s3>CAN</s3><sZ>3 aut.</sZ></fA14><fA14 i1="04"><s1>Queen's Medical Center University Hospital</s1><s2>Nottingham</s2><s3>GBR</s3><sZ>4 aut.</sZ></fA14><fA14 i1="05"><s1>Nottingham Clinical Trials Data Center</s1><s2>Nottingham</s2><s3>GBR</s3><sZ>5 aut.</sZ></fA14><fA14 i1="06"><s1>Flinders Medical Center</s1><s2>Bedford Park</s2><s3>AUS</s3><sZ>6 aut.</sZ></fA14><fA14 i1="07"><s1>University of Sydney</s1><s2>New South Wales</s2><s3>AUS</s3><sZ>7 aut.</sZ></fA14><fA14 i1="08"><s1>Milpark Hospital</s1><s2>Johannesburg</s2><s3>ZAF</s3><sZ>8 aut.</sZ></fA14><fA14 i1="09"><s1>Hospital Clinic, University of Barcelona</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>9 aut.</sZ></fA14><fA14 i1="10"><s1>Medical Clinic of the University of Heidelberg</s1><s2>Heidelberg</s2><s3>DEU</s3><sZ>10 aut.</sZ></fA14><fA14 i1="11"><s1>Green Lane Hospital</s1><s2>Auckland</s2><s3>NZL</s3><sZ>11 aut.</sZ></fA14><fA14 i1="12"><s1>New Zealand; St Lukes-Roosevelt Hospital Center</s1><s2>New York, NY</s2><s3>USA</s3><sZ>12 aut.</sZ></fA14><fA14 i1="13"><s1>Astra Charnwood Clinical R & D</s1><s2>Loughborough</s2><s3>GBR</s3><sZ>13 aut.</sZ></fA14><fA14 i1="14"><s1>Hospital Bichat</s1><s2>Paris</s2><s3>FRA</s3><sZ>14 aut.</sZ></fA14><fA17 i1="01" i2="1"><s1>Behalf of the GUSTO-III Investigators</s1><s3>INC</s3></fA17><fA20><s1>1761-1765</s1></fA20><fA21><s1>2000</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>5907</s2><s5>354000092636000050</s5></fA43><fA44><s0>0000</s0><s1>© 2000 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>14 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>00-0521832</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Circulation : (New York, N.Y.)</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Background-New recombinant plasminogen activators have been developed to simulate the fibrinolytic action of the physiological serine protease tissue plasminogen activator (alteplase, t-PA), and have prolonged half-life features permitting bolus administration. One such activator, reteplase (r-PA), was compared with t-PA in the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-III Trial. Methods and Results-At 1-year follow-up, survival status was ascertained in 97.4% of the 15 059 patients enrolled in the GUSTO-III trial. At 1 year, the mortality rate for the t-PA-assigned group was 11.06%, and for r-PA it was 11.20% (P=0.77). The absolute mortality difference of 0.14% has 95% CIs of - 1.21% to 0.93%. There were no significant differences in outcome by intention-to-treat for the 2 different plasminogen activators in the prespecified groups (age, infarct location, time-to-treatment). The absolute difference in mortality rates between t-PA and r-PA progressively narrowed over the predetermined observation times after random assignment; it was 0.31% at 24 hours, 0.26% at 7 days, 0.23% at 30 days, and 0.14% at I year. Of note, mortality rate in the trial between 30 days and I year in 13 883 patients was 4.02% and did not differ between the treatment groups. However, this mortality rate was substantially greater than in GUSTO-I, in which mortality rate for t-PA versus streptokinase between 30 days and 1-year was 2.97% (heart rate 1.36, 95% CI 1.23, 1.50, P<0.001). Conclusions-The r-PA and t-PA strategies yielded similar survival outcomes after 30 days in this trial. The increase in mortality rate during extended follow-up compared with previous trials may reflect higher-risk patients and highlights the need for improved secondary prevention strategies.</s0></fC01><fC02 i1="01" i2="X"><s0>002B02G</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Infarctus</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Infarct</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Infarto</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Myocarde</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Myocardium</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Miocardio</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Aigu</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Acute</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Agudo</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Altéplase</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Alteplase</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Alteplasa</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Rétéplase</s0><s2>FR</s2><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Reteplase</s0><s2>FR</s2><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Reteplasa</s0><s2>FR</s2><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Streptokinase</s0><s2>NK</s2><s2>FR</s2><s5>07</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Streptokinase</s0><s2>NK</s2><s2>FR</s2><s5>07</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Estreptoquinasa</s0><s2>NK</s2><s2>FR</s2><s5>07</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Chimiothérapie</s0><s5>16</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Chemotherapy</s0><s5>16</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Quimioterapia</s0><s5>16</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Traitement</s0><s5>17</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Treatment</s0><s5>17</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Tratamiento</s0><s5>17</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Pronostic</s0><s5>18</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Prognosis</s0><s5>18</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Pronóstico</s0><s5>18</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Homme</s0><s5>20</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Human</s0><s5>20</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Hombre</s0><s5>20</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Etude longitudinale</s0><s5>23</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Follow up study</s0><s5>23</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Estudio longitudinal</s0><s5>23</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Fibrinolytique</s0><s5>27</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>Fibrinolytic</s0><s5>27</s5></fC03><fC03 i1="12" i2="X" l="SPA"><s0>Fibrinolítico</s0><s5>27</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Appareil circulatoire pathologie</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Cardiovascular disease</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Cardiopathie coronaire</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Coronary heart disease</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Cardiopatía coronaria</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Myocarde pathologie</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Myocardial disease</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Miocardio patología</s0><s5>39</s5></fC07><fN21><s1>346</s1></fN21></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000392 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000392 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:00-0521832
|texte= Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction : Results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial
}}
| This area was generated with Dilib version V0.6.33. |  |